EUCTR2013-001838-17-GB进行中（未招募）1 期
A MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP PLACEBO-CONTROLLED CLINICAL STUDY FOR THE ASSESSMENT OF THE IMMUNOMODULATORY EFFICACY, SAFETY AND CLINICAL IMPACT AFTER THREE AND SIX MONTHS TREATMENT WITH A SUBLINGUAL POLYVALENT BACTERIAL VACCINE (IN ORAL MUCOSA) IN WOMEN WITH RECURRENT URINARY TRACT INFECTIONS (rUTIs). - Evaluation of the Efficacy and Safety of MV140
Syner-Med (PP) Ltd0 个研究点目标入组 240 人开始时间: 2020年8月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •The individuals to be included in the study will meet the following criteria:
- •?Women who have given their informed consent. Age between 18 and 75 years.
- •?Must be able to meet the dosage regimen
- •?Individuals who have had at least 5 episodes of cystitis in the last 12 months.
- •?Individuals who have not responded to hygienic-sanitary measures and / or suppressive treatment and / or postcoital prophylaxis.
- •?Individuals who are free of urinary tract infections at the time of inclusion in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Non- included individuals will be those who/whose:
- •?Have not given their informed consent.
- •?Age is not within the established age range.
- •?Cannot offer cooperation and/or have severe psychiatric disorders
- •?Present a pathologic post-micturition residue.
- •?Present moderate to severe incontinence
- •?Present genital tumors.
- •?Presents Urinary tract tumors.
- •?Present lithiasis
- •?Present alterations in the immune system
- •?Present complicated UTIs
研究者
相似试验
已完成
不适用
A PROSPECTIVE, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, COMPARATIVE STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MK-0826 VERSUS CEFEPIME IN THE TREATMENT OFHOSPITAL-ACQUIRED PNEUMONIA IN ADULTSPER-030-99MERCK SHARP & DOHME PERÚ S.R.L.,
尚未招募
不适用
A PROSPECTIVE, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUPS, PHASE 2B/3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF MASITINIB VERSUS PLACEBO IN THE TREATMENT OF PATIENTS SUFFERING FROM PROGRESSIVE SUPRANUCLEAR PALSY (PSP)PER-026-16AB Science,
已完成
不适用
A PROSPECTIVE, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY AND THE SAFETY OF MASITINIB VERSUS PLACEBO IN THE TREATMENT OF PATIENTS WITH SEVERE UNCONTROLLED ASTHMA AND ELEVATED EOSINOPHIL LEVELS-J450 Predominantly allergic asthmaPredominantly allergic asthmaJ450PER-033-16AB Science,47
进行中（未招募）
不适用
A MULTI-CENTER, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, THIRD PARTY OPEN, PLACEBO CONTROLLED, PILOT STUDY TO ASSESS THE URODYNAMIC EFFECTS OF MODIFIED RELEASE UK-369,003 IN MEN WITH LOWER URINARY TRACT SYMPTOMS (LUTS)EUCTR2006-004380-58-LVPfizer Limited, Ramsgate Road, Sandwich, Kent. UK. CT13 9NJ20
已完成
2 期
A MULTI-CENTER, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, THIRD PARTY OPEN, PLACEBO CONTROLLED, PILOT STUDY TO ASSESS THE URODYNAMIC EFFECTS OF MODIFIED RELEASE UK-369,003 IN MEN WITH LOWER URINARY TRACT SYMPTOMS (LUTS)miction problems10046590NL-OMON30658Pfizer8